APPEAR-C3G (2025) — Trial Summary
APPEAR-C3G (2025): The APPEAR-C3G phase 3 trial evaluated iptacopan, an oral factor B inhibitor, in patients with C3 glomerulopathy (C3G), the first randomized controlled trial to demonstrate efficacy in this rare complement-mediated glomerular disease.
References
- Kavanagh D, Bomback AS, Vivarelli M, et al. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. Lancet. 2025;406(10512):1587-1598.